Essais cliniques en cours et produits autorisés visant PSMA, en radiothérapie interne vectorisée et en imagerie TEP/TEMP. Données du 26 octobre 2026.
Paire théranostique : cette cible est explorée à la fois en imagerie et en thérapie.
| Pluvicto[177Lu]Lu-PSMA-617 (vipivotide tétraxétan) | Novartis | commercialisé | US EU FR JP |
| PSMA-11 (Locametz, Illuccix, Gozellix…)[68Ga]Ga-gozétotide | Novartis, Telix, génériques | commercialisé | US EU FR JP |
| Pylarify / Pylclari[18F]piflufolastat (DCFPyL) | Lantheus (US), Curium (UE) | commercialisé | US EU FR |
| Posluma[18F]flotufolastat (rhPSMA-7.3) | Blue Earth Diagnostics | commercialisé | US |
| Radelumin[18F]PSMA-1007 | ABX | commercialisé (AMM nationales) | EU FR |
| Essai | Phase | Statut | Promoteur | Pays |
|---|---|---|---|---|
| VECTRA-01 · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT07611110 · Prostate – CPRCm | Phase 3 | Recrute | AstraZeneca | 24 |
| PSMAddition · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04720157 · Prostate – hormonosensible | Phase 3 | Actif, ne recrute plus | Novartis Pharmaceuticals | 19 |
| PSMAfore · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04689828 · Prostate – CPRCm | Phase 3 | Actif, ne recrute plus | Novartis Pharmaceuticals | 14 |
| PSMA-DC · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05939414 · Prostate – localisé / récidive | Phase 3 | Recrute | Novartis Pharmaceuticals | 27 |
| SPLASH · [177Lu]Lu-PSMA-I&T (PNT2002/zadavotide)NCT04647526 · Prostate – CPRCm | Phase 3 | Actif, ne recrute plus | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | 6 |
| Rosopatamab (J591)NCT06520345 · Prostate – CPRCm | Phase 3 | Recrute | Telix Pharmaceuticals (Innovations) Pty Limited | 6 |
| PSMAcTION · [225Ac]Ac-PSMA-617 (AAA817)NCT06780670 · Prostate – CPRCm | Phase 3 | Recrute | Novartis Pharmaceuticals | 13 |
| [177Lu]PSMA-I&TNCT05204927 · Prostate – CPRCm | Phase 3 | Actif, ne recrute plus | Curium US LLC | 4 |
| [177Lu]Lu-PSMA-617 (Pluvicto)2022-502408-57-00 · Prostate – hormonosensible | Phase 3 | Recrute | Unicancer | 6 |
| STAMPEDE2 · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06320067 · Prostate – hormonosensible | Phase 3 | Recrute | University College, London | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07200830 · Prostate – CPRCm | Phase 3 | Recrute | Alliance for Clinical Trials in Oncology | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06496581 · Prostate – hormonosensible | Phase 3 | Recrute | UNICANCER | 1 |
| 177Lu-NYM032 injectionNCT07795268 · Prostate – CPRCm | Phase 3 | Pas encore ouvert | Norroy Bioscience Co., LTD | 0 |
| [177Lu]LudotadipepNCT07853209 · Prostate – CPRCm | Phase 3 | Recrute | FutureChem | 1 |
| [177Lu]PSMA-I&T2022-500570-33-00 · Prostate – autre | Phase 3 | Recrute | Region Västerbotten, Umea University | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07852195 · Prostate – CPRCm | Phase 3 | Pas encore ouvert | ECOG-ACRIN Cancer Research Group | 0 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06959433 · Rein | Phase 3 | Pas encore ouvert | Ankara University | 0 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07047118 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Novartis Pharmaceuticals | 15 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT05658003 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Novartis Pharmaceuticals | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT04663997 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Canadian Cancer Trials Group | 1 |
| PRESERVE-006 · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05682443 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | OncoC4, Inc. | 1 |
| PROSPECTOR · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT07590934 · Prostate – autre | Phase 2 | Recrute | AstraZeneca | 7 |
| ENZA-p · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04419402 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 1 |
| PSMACare · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05849298 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Novartis Pharmaceuticals | 11 |
| SPARKLE · [177Lu]Lu-PSMA-617 (Pluvicto)NCT07650240 · Prostate – hormonosensible | Phase 2 | Recrute | Mayo Clinic | 1 |
| AlphaBreak · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT06402331 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Fusion Pharmaceuticals Inc. | 1 |
| [212Pb]Pb-ADVC001 (Phase 1b)NCT05720130 · Prostate – CPRCm | Phase 2 | Recrute | AdvanCell Pty Limited | 1 |
| LUNAR · [177Lu]Lu-PSMA-I&T (PNT2002/zadavotide)NCT05496959 · Prostate – localisé / récidive | Phase 2 | Actif, ne recrute plus | Jonsson Comprehensive Cancer Center | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06084338 · Prostate – CPRCm | Phase 2 | Recrute | VA Office of Research and Development | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06216249 · Prostate – CPRCm | Phase 2 | Recrute | Jonsson Comprehensive Cancer Center | 1 |
| LUST · [177Lu]PSMA-I&TNCT05893381 · Prostate – localisé / récidive | Phase 2 | Recrute | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)2026-525520-20-00 · Prostate – hormonosensible | Phase 2 | Pas encore ouvert | Medical Center - University Of Freiburg | 1 |
| ANDROMEDA · [225Ac]Ac-PSMA-617 (AAA817)NCT07150715 · Prostate – localisé / récidive | Phase 2 | Recrute | Jonsson Comprehensive Cancer Center | 1 |
| [177Lu]rhPSMA-10.1NCT05413850 · Prostate – CPRCm | Phase 2 | Recrute | Blue Earth Therapeutics Ltd | 5 |
| TRC003NCT07567521 · Prostate – CPRCm | Phase 2 | Recrute | C Ray Therapeutics | 1 |
| UpFrontPSMA · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04343885 · Prostate – hormonosensible | Phase 2 | Actif, ne recrute plus | Peter MacCallum Cancer Centre, Australia | 1 |
| POPSTAR II · 177Lu-PSMANCT05560659 · Prostate – localisé / récidive | Phase 2 | Recrute | Peter MacCallum Cancer Centre, Australia | 2 |
| PSMA-ADJUVO · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06449781 · Prostate – localisé / récidive | Phase 2 | Recrute | Maria Sklodowska-Curie National Research Institute of Oncology | 1 |
| CATCH-177 · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06738303 · Prostate – CPRCm | Phase 2 | Recrute | Case Comprehensive Cancer Center | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07226986 · Prostate – CPRCm | Phase 2 | Recrute | Novartis Pharmaceuticals | 7 |
| Rosopatamab (J591)NCT00859781 · Prostate – localisé / récidive | Phase 2 | Actif, ne recrute plus | Weill Medical College of Cornell University | 1 |
| PREDICT · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06632977 · Prostate – CPRCm | Phase 2 | Recrute | Alliance for Clinical Trials in Oncology | 1 |
| ARREST · Standard of care 177Lutetium-PSMANCT07354594 · Prostate – CPRCm | Phase 2 | Recrute | Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07550517 · Prostate – autre | Phase 2 | Recrute | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| Rosopatamab (J591)NCT06549465 · Prostate – CPRCm | Phase 2 | Recrute | Convergent Therapeutics | 1 |
| PSMAndARPI · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06894511 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Novartis Pharmaceuticals | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)2026-527059-25-00 · Prostate – CPRCm | Phase 2 | Pas encore ouvert | Benfovir AG | 1 |
| Lutetium Lu 177 JH020002 InjectionNCT06139575 · Prostate – autre | Phase 2 | Recrute | Bivision Pharmaceuticals, Inc. | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07698535 · Prostate – CPRCm | Phase 2 | Recrute | University of Washington | 1 |
| Rosopatamab (J591)NCT04946370 · Prostate – CPRCm | Phase 2 | Recrute | Weill Medical College of Cornell University | 1 |
| ReaLuP · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06866938 · Prostate – CPRCm | Phase 2 | Recrute | Hospices Civils de Lyon | 1 |
| [225Ac]/[177Lu]PSMA-R22023-507672-52-00 · Prostate – CPRCm | Phase 2 | Recrute | Novartis Pharma AG | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06526299 · Prostate – CPRCm | Phase 2 | Recrute | University of Washington | 1 |
| PluvEquity · [177Lu]Lu-PSMA-617 (Pluvicto)NCT07860554 · Prostate – CPRCm | Phase 2 | Pas encore ouvert | Emory University | 1 |
| PRODIGY-1 · [177Lu]PSMA-I&TNCT05896371 · Prostate – autre | Phase 2 | Pas encore ouvert | CHU de Quebec-Universite Laval | 0 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06004661 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Novartis Pharmaceuticals | 5 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06039371 · Prostate – CPRCm | Phase 2 | Recrute | University of Washington | 1 |
| TATCIST · [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT05219500 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Fusion Pharmaceuticals Inc. | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT05766371 · Prostate – CPRCm | Phase 2 | Recrute | University of California, San Francisco | 1 |
| RENALUT · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06783348 · Rein | Phase 2 | Recrute | European Organisation for Research and Treatment of Cancer - EORTC | 1 |
| [225Ac]AZD2265 (ex-FPI-2265, PSMA-I&T)NCT06909825 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Fusion Pharmaceuticals Inc. | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06288113 · Prostate – CPRCm | Phase 2 | Recrute | Jonsson Comprehensive Cancer Center | 1 |
| 177Lu-PSMA-0057NCT07310355 · Prostate – CPRCm | Phase 2 | Pas encore ouvert | Chengdu StarRay Therapeutics Co., Ltd | 0 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06972628 · Prostate – CPRCm | Phase 2 | Recrute | Ebrahim S Delpassand | 1 |
| TeLuNa · [161Tb]/[177Lu]PSMA-I&TNCT07441837 · Prostate – CPRCm | Phase 2 | Pas encore ouvert | Ankara University | 1 |
| LUBASKET · [177Lu]PSMA-I&TNCT05867615 · Tumeurs solides (multi-indications) | Phase 2 | Actif, ne recrute plus | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 1 |
| STARLiT · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06574880 · Prostate – autre | Phase 2 | Recrute | Angela Y. Jia, MD PhD | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)2026-525776-26-00 · ORL | Phase 2 | Pas encore ouvert | Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy | 1 |
| SECuRE · 67Cu-SAR-bisPSMANCT04868604 · Prostate – CPRCm | Phase 2 | Recrute | Clarity Pharmaceuticals Ltd | 1 |
| [177Lu]PSMA-I&T2026-527110-23-00 · Prostate – CPRCm | Phase 2 | Pas encore ouvert | Region Uppsala | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07737925 · Prostate – CPRCm | Phase 2 | Pas encore ouvert | Thomas Jefferson University | 0 |
| LASER · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06964958 · Rein | Phase 2 | Actif, ne recrute plus | Dana-Farber Cancer Institute | 1 |
| 225Ac-LNC1011NCT07117760 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | First Affiliated Hospital of Fujian Medical University | 1 |
| ACT-RESoLUTE · [177Lu]rhPSMA-10.1NCT07414940 · Prostate – CPRCm | Phase 2 | Recrute | University College, London | 1 |
| 177Lu HTK03170NCT05570994 · Prostate – CPRCm | Phase 2 | Sur invitation | British Columbia Cancer Agency | 1 |
| [177Lu]PSMA-I&TNCT06220188 · Prostate – localisé / récidive | Phase 2 | Recrute | Medical University of Vienna | 1 |
| 177Lu-P17-088NCT07562438 · Prostate – CPRCm | Phase 2 | Recrute | First Affiliated Hospital of Fujian Medical University | 1 |
| AlphaBet · [177Lu]PSMA-I&TNCT05383079 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Peter MacCallum Cancer Centre, Australia | 1 |
| 177Lu-NYM032 injectionNCT06383052 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Norroy Bioscience Co., LTD | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06798558 · Prostate – localisé / récidive | Phase 2 | Recrute | Hackensack Meridian Health | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)2022-500838-28-00 · Prostate – localisé / récidive | Phase 2 | Recrute | Universitaetsklinikum Essen AöR | 1 |
| [177Lu]PSMA-I&T2023-504696-24-00 · Cerveau (gliome, médulloblastome…) | Phase 2 | Pas encore ouvert | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | 2 |
| PRO-XL · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06568562 · Prostate – CPRCm | Phase 2 | Recrute | University of Utah | 1 |
| VIOLET · [161Tb]PSMA-I&TNCT05521412 · Prostate – CPRCm | Phase 2 | Recrute | Peter MacCallum Cancer Centre, Australia | 1 |
| ERD2021 · Radiopharmaceutical 68Ga-PSMANCT05214820 · Estomac / œsophage | Phase 2 | Actif, ne recrute plus | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 1 |
| 225Ac-LNC1011NCT07363486 · Prostate – CPRCm | Phase 2 | Recrute | First Affiliated Hospital of Fujian Medical University | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06145633 · Prostate – CPRCm | Phase 2 | Recrute | Fred Hutchinson Cancer Center | 1 |
| UPLIFT · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05113537 · Prostate – CPRCm | Phase 2 | Recrute | Vadim S Koshkin | 1 |
| LuCAB · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05340374 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | Peter MacCallum Cancer Centre, Australia | 1 |
| RLT PSMA après testostérone haute doseNCT07476001 · Prostate – CPRCm | Phase 2 | Recrute | H. Lee Moffitt Cancer Center and Research Institute | 1 |
| [177Lu]PSMA-I&TNCT06259123 · Prostate – localisé / récidive | Phase 2 | Recrute | Medical University of Vienna | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06852820 · Foie (CHC) | Phase 2 | Recrute | Melissa Lumish | 1 |
| LuTectomy · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04430192 · Prostate – localisé / récidive | Phase 2 | Actif, ne recrute plus | Peter MacCallum Cancer Centre, Australia | 1 |
| 30 mCi NYMO32NCT06827080 · Prostate – CPRCm | Phase 2 | Pas encore ouvert | Zhengguo Chen | 0 |
| [177Lu]PSMA-I&T2026-526519-12-00 · Prostate – CPRCm | Phase 2 | Pas encore ouvert | Universitetssykehuset Nord-Norge HF | 1 |
| [177Lu]rhPSMA-10.1NCT06066437 · Prostate – autre | Phase 2 | Recrute | M.D. Anderson Cancer Center | 1 |
| PAnTHA · 225Ac-PSMA-Trillium (BAY3563254)NCT06217822 · Prostate – CPRCm | Phase 1 | Recrute | Bayer | 10 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06095089 · Prostate – autre | Phase 1 | Recrute | Janssen Research & Development, LLC | 5 |
| BAY3546828NCT06052306 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Bayer | 4 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07219147 · Prostate – CPRCm | Phase 1 | Recrute | City of Hope Medical Center | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT05818683 · Prostate – CPRCm | Phase 1 | Recrute | Janssen Research & Development, LLC | 3 |
| PRODIGY-2 · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06943495 · Prostate – CPRCm | Phase 1 | Recrute | Jean-Mathieu Beauregard | 1 |
| RADIODOSE · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06531499 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Novartis Pharmaceuticals | 6 |
| SatisfACtion · [225Ac]/[177Lu]PSMA-R2NCT05983198 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Novartis Pharmaceuticals | 4 |
| [177Lu]DGUL (Cellbion)NCT07244393 · Prostate – CPRCm | Phase 1 | Recrute | Cellbion Co., Ltd. | 1 |
| PROGNOSTICS · [161Tb]/[177Lu]PSMA-I&TNCT06343038 · Prostate – CPRCm | Phase 1 | Recrute | University Hospital, Basel, Switzerland | 1 |
| [225Ac]AZD2284NCT06879041 · Prostate – CPRCm | Phase 1 | Recrute | AstraZeneca | 3 |
| [225Ac]Ac-PSMA-617 (AAA817)NCT04597411 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Endocyte | 2 |
| ACCEL · [Ac-225]-PSMA-62 (mCRPC)NCT06229366 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Eli Lilly and Company | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06379217 · Prostate – autre | Phase 1 | Actif, ne recrute plus | Novartis Pharmaceuticals | 5 |
| 1.1 GBq (30 mCi) of 177Lu-P17-087NCT05603559 · Prostate – CPRCm | Phase 1 | Recrute | Peking Union Medical College Hospital | 1 |
| ProTACT · [225Ac]FL-020NCT06492122 · Prostate – CPRCm | Phase 1 | Recrute | Full-Life Technologies UK Limited | 4 |
| ARTISAN · [212Pb]AB001NCT07214961 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | ARTBIO Inc. | 1 |
| LumOnate · [177Lu]PSMA-I&TNCT07090369 · Prostate – CPRCm | Phase 1 | Pas encore ouvert | Peter MacCallum Cancer Centre, Australia | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07145177 · Prostate – CPRCm | Phase 1 | Recrute | University of California, San Francisco | 1 |
| 177Lu-FC516NCT07542379 · Prostate – autre | Phase 1 | Recrute | FindCure Biosciences (ZhongShan) Co., Ltd. | 1 |
| LuPARP · [177Lu]Lu-PSMA-617 (Pluvicto)NCT03874884 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Peter MacCallum Cancer Centre, Australia | 1 |
| Rosopatamab (J591)NCT04506567 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Weill Medical College of Cornell University | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT06303713 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Dana-Farber Cancer Institute | 1 |
| [177Lu]Lu-PSMA-XTNCT07096128 · Prostate – CPRCm | Phase 1 | Recrute | Jinming Zhang | 1 |
| 177Lu-PSMA-VG01NCT07660211 · Prostate – CPRCm | Phase 1 | Recrute | VitsGen Therapeutics Inc. | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT05079698 · Prostate – hormonosensible | Phase 1 | Actif, ne recrute plus | Memorial Sloan Kettering Cancer Center | 1 |
| LUTACT · [225Ac]Ac-PSMA-617 (AAA817)NCT07054346 · Prostate – autre | Phase 1 | Recrute | Thomas Hope | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT04886986 · Prostate – CPRCm | Phase 1 | Recrute | Weill Medical College of Cornell University | 1 |
| 225Ac-PSMA-XTNCT07135102 · Prostate – CPRCm | Phase 1 | Recrute | Xiaorong Sun | 1 |
| [225Ac]PSMA-I&T2024-513729-22-01 · Prostate – autre | Phase 1 | Recrute | Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC) | 1 |
| CaboLu · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05613894 · Prostate – CPRCm | Phase 1 | Recrute | University of Utah | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)NCT07223034 · Cerveau (gliome, médulloblastome…) | Phase 1 | Recrute | Memorial Sloan Kettering Cancer Center | 1 |
| PRadR2 · 161Tb-PSMA-1 (radiopharmaceutical)NCT07828249 · Rein | Phase 1 | Pas encore ouvert | Centre Leon Berard | 1 |
| [177Lu]Lu-PSMA-617 (Pluvicto)2025-524027-49-00 · Sein | Phase 1 | Pas encore ouvert | Universitaetsklinikum Aachen AöR | 1 |
| [177Lu]PSMA-I&TNCT07316686 · Prostate – CPRCm | Phase 1 | Recrute | Instituto do Cancer do Estado de São Paulo | 1 |
| ESCENDO · [177Lu]Lu-PSMA-617 (Pluvicto)NCT07682649 · Prostate – CPRCm | Phase 1 | Pas encore ouvert | University of Michigan Rogel Cancer Center | 1 |
| Alpha-PS1 · [211At]PSMA-5 (PSW-1025)NCT06441994 · Prostate – CPRCm | Phase 1 | Actif, ne recrute plus | Osaka University | 1 |
| 161Tb-LNC1011 · 161Tb-LNC1011NCT07381582 · Prostate – CPRCm | Phase 1 | Pas encore ouvert | Peking Union Medical College Hospital | 1 |
| [177Lu]Lu-PSMA-137NCT06546527 · Prostate – CPRCm | Phase 1 | Pas encore ouvert | Peking University First Hospital | 0 |
| [161Tb]PSMA-I&TNCT07621692 · Prostate – CPRCm | Phase 1 | Recrute | National Taiwan University Hospital | 1 |
| [177Lu]rhPSMA-10.1NCT06105918 · Prostate – localisé / récidive | Phase 1 | Actif, ne recrute plus | Emory University | 1 |
| Lu 177-PSMA-3D1015 InjectionNCT07537010 · Prostate – CPRCm | Phase 1 | Recrute | Chunjing Yu | 1 |
| Essai | Phase | Statut | Promoteur | Pays |
|---|---|---|---|---|
| Autre ligand PSMA2023-505852-23-00 · Prostate – hormonosensible | Phase 3 | Recrute | Janssen - Cilag International | 13 |
| CLARIFY · [64Cu]SAR-bisPSMANCT06056830 · Prostate – localisé / récidive | Phase 3 | Recrute | Clarity Pharmaceuticals Ltd | 3 |
| [18F]PSMA-1007NCT06122584 · Prostate – localisé / récidive | Phase 3 | Recrute | ABX advanced biochemical compounds GmbH | 6 |
| Solar-Stage · Autre ligand PSMANCT06235151 · Prostate – localisé / récidive | Phase 3 | Actif, ne recrute plus | Curium US LLC | 1 |
| Autre ligand PSMANCT05004285 · Prostate – autre | Phase 3 | Actif, ne recrute plus | FutureChem | 1 |
| Autre ligand PSMANCT07615101 · Prostate – autre | Phase 3 | Recrute | Norroy Bioscience Co., LTD | 1 |
| Autre ligand PSMANCT07649122 · Prostate – localisé / récidive | Phase 3 | Recrute | Norroy Bioscience Co., LTD | 1 |
| Autre ligand PSMANCT05936658 · Prostate – localisé / récidive | Phase 3 | Actif, ne recrute plus | FutureChem | 1 |
| [68Ga]Ga-PSMA-112023-504917-54-00 · Prostate – localisé / récidive | Phase 3 | Recrute | Karolinska University Hospital | 1 |
| PSMA SRT · [68Ga]Ga-PSMA-11NCT03582774 · Prostate – autre | Phase 3 | Actif, ne recrute plus | Jonsson Comprehensive Cancer Center | 1 |
| BiPASS · [68Ga]Ga-PSMA-11NCT07052214 · Prostate – autre | Phase 3 | Actif, ne recrute plus | Telix Pharmaceuticals (Innovations) Pty Limited | 2 |
| [68Ga]Ga-PSMA-112023-506032-33-00 · Prostate – localisé / récidive | Phase 3 | Pas encore ouvert | Universitaetsklinikum Essen AöR | 1 |
| AMPLIFY · [64Cu]SAR-bisPSMANCT06970847 · Prostate – localisé / récidive | Phase 3 | Actif, ne recrute plus | Clarity Pharmaceuticals Ltd | 2 |
| [68Ga]Ga-PSMA-112024-518171-59-00 · Prostate – autre | Phase 3 | Recrute | Canisius Wilhelmina Ziekenhuis | 1 |
| [18F]DCFPyL (piflufolastat)NCT03594760 · Prostate – autre | Phase 3 | Recrute | Centre hospitalier de l'Université de Montréal (CHUM) | 1 |
| [18F]PSMA-1007NCT05520255 · Prostate – autre | Phase 3 | Recrute | University of Alberta | 1 |
| Autre ligand PSMANCT06565247 · Prostate – localisé / récidive | Phase 3 | Recrute | Region Västerbotten | 1 |
| [18F]DCFPyL (piflufolastat)NCT03824275 · Prostate – autre | Phase 3 | Actif, ne recrute plus | Columbia University | 1 |
| [68Ga]Ga-PSMA-11NCT07209878 · Prostate – autre | Phase 3 | Recrute | First Affiliated Hospital of Fujian Medical University | 1 |
| [18F]DCFPyL (piflufolastat)NCT03459820 · Prostate – autre | Phase 3 | Sur invitation | Sir Mortimer B. Davis - Jewish General Hospital | 1 |
| [18F]DCFPyL (piflufolastat)NCT03495427 · Prostate – autre | Phase 3 | Recrute | H. Lee Moffitt Cancer Center and Research Institute | 1 |
| [68Ga]Ga-PSMA-112024-514181-39-00 · Rein | Phase 3 | Recrute | Stichting Radboud universitair medisch centrum | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT05678322 · Prostate – localisé / récidive | Phase 3 | Actif, ne recrute plus | NYU Langone Health | 1 |
| P-GAP · [18F]PSMA-1007NCT06003556 · Prostate – autre | Phase 2 | Recrute | University of Alberta | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT07593079 · Prostate – localisé / récidive | Phase 2 | Pas encore ouvert | Washington University School of Medicine | 1 |
| [18F]DCFPyL (piflufolastat)NCT03173924 · Prostate – autre | Phase 2 | Actif, ne recrute plus | National Cancer Institute (NCI) | 1 |
| Autre ligand PSMANCT03444844 · Prostate – localisé / récidive | Phase 2 | Actif, ne recrute plus | Five Eleven Pharma, Inc. | 1 |
| [18F]DCFPyL (piflufolastat)NCT03471650 · Prostate – autre | Phase 2 | Actif, ne recrute plus | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 1 |
| RF2021-1237227 · Autre ligand PSMANCT06305390 · Prostate – autre | Phase 2 | Recrute | IRCCS San Raffaele | 1 |
| [68Ga]Ga-PSMA-11NCT03181867 · Prostate – localisé / récidive | Phase 2 | Actif, ne recrute plus | National Cancer Institute (NCI) | 1 |
| ECLIPSE · [18F]rhPSMA-7.3 (flotufolastat)NCT07185165 · Prostate – autre | Phase 2 | Recrute | Jonsson Comprehensive Cancer Center | 1 |
| [18F]DCFPyL (piflufolastat)NCT03976843 · Prostate – localisé / récidive | Phase 2 | Actif, ne recrute plus | National Cancer Institute (NCI) | 1 |
| Autre ligand PSMANCT07056790 · Prostate – autre | Phase 2 | Recrute | First Affiliated Hospital of Fujian Medical University | 1 |
| [18F]DCFPyL (piflufolastat)NCT06904313 · Prostate – autre | Phase 2 | Recrute | Akiva Mintz | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT06617481 · Prostate – localisé / récidive | Phase 2 | Recrute | AdventHealth | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT07220720 · Prostate – autre | Phase 2 | Recrute | University of Florida | 1 |
| [18F]DCFPyL (piflufolastat)NCT07635524 · Prostate – autre | Phase 2 | Pas encore ouvert | Hoag Memorial Hospital Presbyterian | 1 |
| Autre ligand PSMANCT05761366 · Prostate – autre | Phase 2 | Recrute | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 1 |
| [99mTc]PSMA2026-526915-12-00 · Prostate – autre | Phase 2 | Pas encore ouvert | Ospedale San Raffaele S.r.l. | 1 |
| [18F]DCFPyL (piflufolastat)NCT04700332 · Prostate – localisé / récidive | Phase 2 | Recrute | Hoag Memorial Hospital Presbyterian | 1 |
| [68Ga]Ga-PSMA-112024-517098-26-00 · Rein | Phase 2 | Recrute | Cliniques Universitaires Saint-Luc | 1 |
| [68Ga]Ga-PSMA-11NCT04777071 · Prostate – CPRCm | Phase 2 | Actif, ne recrute plus | University of Washington | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT07285057 · Prostate – autre | Phase 2 | Recrute | Icahn School of Medicine at Mount Sinai | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT05779943 · Prostate – localisé / récidive | Phase 2 | Actif, ne recrute plus | Emory University | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT06865768 · Prostate – autre | Phase 2 | Recrute | Emory University | 1 |
| Autre ligand PSMA2023-505453-40-00 · Prostate – autre | Phase 2 | Pas encore ouvert | Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting | 1 |
| ERD2021 · Autre ligand PSMANCT05214820 · Estomac / œsophage | Phase 2 | Actif, ne recrute plus | Centre de recherche du Centre hospitalier universitaire de Sherbrooke | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT07568756 · Prostate – autre | Phase 2 | Pas encore ouvert | University of California, Irvine | 1 |
| [68Ga]Ga-PSMA-112022-503036-13-00 · Prostate – autre | Phase 2 | Recrute | Universitair Ziekenhuis Gent | 1 |
| [68Ga]Ga-PSMA-112023-508709-26-00 · Foie (CHC) | Phase 2 | Recrute | Universitair Ziekenhuis Gent | 1 |
| [68Ga]Ga-PSMA-11NCT06444412 · Cerveau (gliome, médulloblastome…) | Phase 2 | Recrute | Mayo Clinic | 1 |
| PPPIMS · Autre ligand PSMANCT06560905 · Mélanome | Phase 2 | Recrute | Royal Marsden NHS Foundation Trust | 1 |
| [18F]DCFPyL (piflufolastat)2026-525181-22-00 · Prostate – autre | Phase 1 | Pas encore ouvert | Centre Hospitalier Universitaire De Toulouse | 1 |
| [68Ga]Ga-PSMA-11NCT05160597 · Prostate – autre | Phase 1 | Actif, ne recrute plus | Jonsson Comprehensive Cancer Center | 1 |
| [18F]DCFPyL (piflufolastat)NCT06586047 · Sein | Phase 1 | Recrute | Ahmad Shariftabrizi | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT06813898 · Prostate – autre | Phase 1 | Recrute | Northwestern University | 1 |
| [18F]DCFPyL (piflufolastat)NCT05394259 · Sein | Phase 1 | Actif, ne recrute plus | M.D. Anderson Cancer Center | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT05852041 · Prostate – autre | Phase 1 | Recrute | Northwestern University | 1 |
| Autre ligand PSMANCT06864572 · Prostate – autre | Phase 1 | Sur invitation | Peking Union Medical College Hospital | 1 |
| [99mTc]PSMANCT04857502 · Prostate – autre | Phase 1 | Recrute | Jonsson Comprehensive Cancer Center | 1 |
| [18F]DCFPyL (piflufolastat)NCT06756334 · Prostate – localisé / récidive | Phase 1 | Recrute | Anhui Provincial Hospital | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT07149831 · Prostate – autre | Phase 1 | Recrute | Sinotau Pharmaceutical Group | 1 |
| [18F]DCFPyL (piflufolastat)NCT03392181 · Prostate – autre | Phase 1 | Actif, ne recrute plus | Northwestern University | 1 |
| [68Ga]Ga-PSMA-11NCT06209567 · Cerveau (gliome, médulloblastome…) | Phase 1 | Actif, ne recrute plus | Memorial Sloan Kettering Cancer Center | 1 |
| [68Ga]Ga-PSMA-11NCT04147494 · Prostate – autre | Phase 1 | Actif, ne recrute plus | Jonsson Comprehensive Cancer Center | 1 |
| Autre ligand PSMANCT05562791 · Vessie / urothélial | Phase 1 | Recrute | Memorial Sloan Kettering Cancer Center | 1 |
| Autre ligand PSMANCT06387381 · Autre | Phase 1 | Recrute | First Affiliated Hospital of Chongqing Medical University | 1 |
| [68Ga]Ga-PSMA-11NCT06419348 · Prostate – autre | Phase 1 | Recrute | First Affiliated Hospital of Chongqing Medical University | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT07164027 · Prostate – autre | Phase 1 | Recrute | Jonsson Comprehensive Cancer Center | 1 |
| Autre ligand PSMANCT04167969 · Prostate – autre | Phase 1 | Recrute | Memorial Sloan Kettering Cancer Center | 1 |
| Autre ligand PSMANCT06736054 · Prostate – autre | Phase 1 | Recrute | Hoag Memorial Hospital Presbyterian | 1 |
| MIRROR · [18F]DCFPyL (piflufolastat)NCT06074510 · Prostate – autre | Sans phase | Actif, ne recrute plus | Lantheus Medical Imaging | 1 |
| Autre ligand PSMANCT06219746 · Prostate – autre | Sans phase | Recrute | Turku University Hospital | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT07115277 · Prostate – localisé / récidive | Sans phase | Recrute | Sinotau Pharmaceutical Group | 1 |
| Autre ligand PSMANCT07386496 · Prostate – autre | Sans phase | Pas encore ouvert | Chinese University of Hong Kong | 1 |
| Autre ligand PSMANCT07301827 · Rein | Sans phase | Recrute | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| [99mTc]PSMANCT05847166 · Prostate – autre | Sans phase | Recrute | NCBJ Polatom: Narodowe Centrum Badań Jądrowych Polatom | 1 |
| [68Ga]Ga-PSMA-11NCT06696326 · Prostate – autre | Sans phase | Recrute | The First Affiliated Hospital of Xiamen University | 1 |
| GUIDE PSMA PET · Autre ligand PSMANCT07258056 · Prostate – autre | Sans phase | Recrute | Mads Ryo Jochumsen | 1 |
| Autre ligand PSMANCT05324332 · Prostate – autre | Sans phase | Recrute | Peking Union Medical College Hospital | 1 |
| GIPSMA · Autre ligand PSMANCT05547919 · TNE gastro-entéro-pancréatiques | Sans phase | Recrute | Wuerzburg University Hospital | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT06389786 · Prostate – localisé / récidive | Sans phase | Recrute | Mayo Clinic | 1 |
| PRIDE2-PC · [18F]PSMA-1007NCT07568613 · Prostate – autre | Sans phase | Recrute | German Oncology Center, Cyprus | 1 |
| HIMIKO · [68Ga]Ga-PSMA-11NCT06999837 · Foie (CHC) | Sans phase | Recrute | Nantes University Hospital | 1 |
| Autre ligand PSMANCT07324733 · Autre | Sans phase | Recrute | Peking Union Medical College Hospital | 1 |
| Autre ligand PSMANCT04987086 · Rein | Sans phase | Recrute | Xijing Hospital | 1 |
| Autre ligand PSMANCT05887687 · Tumeurs solides (multi-indications) | Sans phase | Recrute | Peking University First Hospital | 1 |
| Autre ligand PSMANCT07511933 · Poumon à petites cellules | Sans phase | Recrute | The Netherlands Cancer Institute | 1 |
| [18F]DCFPyL (piflufolastat)NCT05919329 · Prostate – CPRCm | Sans phase | Recrute | OHSU Knight Cancer Institute | 1 |
| [18F]PSMA-1007NCT06723665 · Prostate – autre | Sans phase | Sur invitation | Affiliated Hospital of Jiangnan University | 1 |
| INTROSPECT · [68Ga]Ga-PSMA-11NCT07829068 · Prostate – localisé / récidive | Sans phase | Actif, ne recrute plus | University Hospital, Geneva | 1 |
| PSMA-AS · Autre ligand PSMANCT06866041 · Prostate – autre | Sans phase | Recrute | Università Vita-Salute San Raffaele | 1 |
| TAYLOR · Autre ligand PSMANCT06917781 · Prostate – autre | Sans phase | Recrute | Institut Claudius Regaud | 1 |
| PYPET · Autre ligand PSMANCT06450548 · Prostate – autre | Sans phase | Recrute | Centre Henri Becquerel | 1 |
| SCOUT · [18F]rhPSMA-7.3 (flotufolastat)NCT07011342 · Prostate – autre | Sans phase | Recrute | Hackensack Meridian Health | 1 |
| Autre ligand PSMANCT07639801 · Prostate – autre | Sans phase | Pas encore ouvert | Peking University Cancer Hospital & Institute | 0 |
| [99mTc]P137NCT05672485 · Prostate – autre | Sans phase | Recrute | First Affiliated Hospital Xi'an Jiaotong University | 1 |
| [18F]DCFPyL (piflufolastat)NCT05470699 · Prostate – autre | Sans phase | Actif, ne recrute plus | City of Hope Medical Center | 1 |
| Autre ligand PSMANCT05940259 · Prostate – autre | Sans phase | Recrute | Peking University First Hospital | 1 |
| [18F]DCFPyL (piflufolastat)NCT06099093 · Prostate – CPRCm | Sans phase | Recrute | Brigham and Women's Hospital | 1 |
| [68Ga]Ga-PSMA-11NCT06335914 · Prostate – autre | Sans phase | Recrute | University Health Network, Toronto | 1 |
| [68Ga]Ga-PSMA-11NCT07365397 · Prostate – autre | Sans phase | Pas encore ouvert | Shanghai Zhongshan Hospital | 0 |
| IAPSMA · Autre ligand PSMANCT07656337 · Prostate – autre | Sans phase | Pas encore ouvert | Lithuanian University of Health Sciences | 1 |
| Autre ligand PSMANCT07819760 · Prostate – localisé / récidive | Sans phase | Recrute | Botkin Hospital | 1 |
| Autre ligand PSMANCT05647564 · Prostate – CPRCm | Sans phase | Recrute | University of Wisconsin, Madison | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT06479187 · Prostate – hormonosensible | Sans phase | Actif, ne recrute plus | Brigham and Women's Hospital | 1 |
| [18F]rhPSMA-7.3 (flotufolastat)NCT06580015 · Prostate – autre | Sans phase | Actif, ne recrute plus | City of Hope Medical Center | 1 |
| PSMA · Autre ligand PSMANCT07162779 · Prostate – autre | Sans phase | Sur invitation | Affiliated Hospital of Jiangnan University | 1 |
PSMA. Theranostic Atlas, LaRadiopharmacie.fr. Données du 26 octobre 2026. https://theranosticatlas.com/fr/target/psma/ (consulté le [date]).
Outil de veille sans valeur réglementaire : vérifier chaque donnée à sa source.